• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

作者信息

Dwyer Jamie P, Maklad Noha, Vedin Ola, Monyak John, Myte Robin, Chertow Glenn M, Heerspink Hiddo J L, Little Dustin J

机构信息

Division of Nephrology and Hypertension, University of Utah, Salt Lake City, Utah.

Late Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.

出版信息

J Am Soc Nephrol. 2025 Sep 6. doi: 10.1681/ASN.0000000849.

DOI:10.1681/ASN.0000000849
PMID:40913594
Abstract
摘要

相似文献

1
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.巴多司他对慢性肾脏病合并未控制高血压患者的疗效与安全性：一项随机、双盲、安慰剂对照试验
J Am Soc Nephrol. 2025 Sep 6. doi: 10.1681/ASN.0000000849.
2
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.巴多司他治疗未控制及难治性高血压的疗效与安全性
N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2507109.
3
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24.用于治疗难治性高血压的巴多司他：3期临床试验BaxHTN、BaxAsia和Bax24的原理与设计
Hypertens Res. 2025 Aug 25. doi: 10.1038/s41440-025-02297-7.
4
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.巴多司他治疗顽固性高血压的2期试验。
N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.
5
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.洛伦德司他用于未控制高血压和顽固性高血压患者：Launch-HTN随机临床试验
JAMA. 2025 Jun 30. doi: 10.1001/jama.2025.9413.
6
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.醛固酮合酶抑制剂维卡司他（BI 690517）改善慢性肾脏病心肾结局的潜力：EASi-KIDNEY试验的理论依据
Nephrol Dial Transplant. 2025 May 30;40(6):1175-1186. doi: 10.1093/ndt/gfae263.
7
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.洛伦德司他对血压控制不佳患者的疗效与安全性
N Engl J Med. 2025 May 8;392(18):1813-1823. doi: 10.1056/NEJMoa2501440. Epub 2025 Apr 23.
8
Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial.益气培元颗粒改善急性肾损伤患者近期预后的有效性和安全性：一项多中心、双盲、安慰剂对照、随机临床试验。
J Integr Med. 2024 May;22(3):279-285. doi: 10.1016/j.joim.2024.04.004. Epub 2024 Apr 23.
9
Efficacy and safety of ayurvedic intervention (Sarpgandha Mishran) vs amlodipine for Stage-I primary hypertension- study protocol for a prospective Double-Dummy, Double-Blind, placebo-controlled Randomized Clinical Trial.阿育吠陀干预（蛇根木合剂）与氨氯地平治疗I期原发性高血压的疗效和安全性——一项前瞻性双模拟、双盲、安慰剂对照随机临床试验的研究方案
BMC Complement Med Ther. 2025 Mar 1;25(1):88. doi: 10.1186/s12906-025-04802-4.
10
Clinical Decision Support for Hypertension Management in Chronic Kidney Disease: A Randomized Clinical Trial.临床决策支持在慢性肾脏病高血压管理中的应用：一项随机临床试验。
JAMA Intern Med. 2024 May 1;184(5):484-492. doi: 10.1001/jamainternmed.2023.8315.